82040-90-2

Basic information

• Product Name: Benzene, 1-(3-chloropropoxy)-2-methoxy-4-nitro-
• CAS NO: 82040-90-2
• Molecular Formula: C10H12ClNO4
• Molecular Weight: 245.663
• Mol File: 82040-90-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(3-chloropropoxy)-2-methoxy-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(3-chloropropoxy)-2-methoxy-4-nitro-(82040-90-2)
• EPA Substance Registry System: Benzene, 1-(3-chloropropoxy)-2-methoxy-4-nitro-(82040-90-2)

Safety Data

• Hazardous Substances Data: 82040-90-2(Hazardous Substances Data)

Upstream product

• 3251-56-7 2-methoxy-4-nitrophenol 
• 109-70-6 1.3-chlorobromopropane 
• 142-28-9 1,3-Dichloropropane 

Downstream Products

• 700804-30-4 4-amino-2-methoxy-[3-(morpholin-4-yl)propoxy]benzene 
• 700804-28-0 3-methoxy-4-(3'-N-morpholino)propoxynitro-benzene 
• 835633-56-2 3-methoxy-4-(3-(4-methylpiperazin-1-yl)propoxy)aniline 
• 1015077-06-1 1-(3-(2-methoxy-4-nitrophenoxy)propyl)-4-methylpiperazine 
• 67438-15-7 1-(2-methoxy-4-nitrophenoxy)-3-anilinopropane 

Relevant articles and documents

JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma

JAK3 is predominantly expressed in hematopoietic cells and has been a promising therapeutic target for the treatment of B-cell lymphoma. In this study, a new class of thieno[3,2-d]pyrimidines harboring acrylamide pharmacophore were synthesized as potent covalent JAK3 inhibitors (IC50 50 values of 1.9 nM and 1.8 nM, respectively. Furthermore, compared with the reference agents, Spebrutinib and Ibrutinib, 9a not only demonstrated enhanced antiproliferative activity against B lymphoma cells, but also showed very weak proliferative inhibition against normal peripheral blood mononuclear cells (PBMCs) at a concentration of 20 μM. Analysis of the mechanism revealed that 9a could induce the obvious apoptosis in B lymphoma cells and prevent JAK3-STAT3 cascade as well as BTK pathway. Taken together, 9a may be served as a potential new JAK3 inhibitor for the treatment of B-cell lymphoma.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5′, 4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): Synthesis, SAR, and in vivo anti-inflammatory activity

Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological characterization of 2-amino-6-phenylpyrimido[5′,4′:5,6]pyrimido[1,2- a]benzimidazol-5(6H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2- ((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5′,4′:5,6] pyrimido-[1,2-a]benzimidazol-5(6H)-one (25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.

DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

-